{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2&page=42",
    "query": {
      "intervention": "Dose 2",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 31384,
    "total_pages": 3139,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+2&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T17:04:46.742Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03818542",
      "title": "A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "ABBV-181",
          "type": "DRUG"
        },
        {
          "name": "ABBV-368",
          "type": "DRUG"
        },
        {
          "name": "ABBV-927",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2020-01-22",
      "completion_date": "2020-09-23",
      "has_results": false,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818542"
    },
    {
      "nct_id": "NCT03687827",
      "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 498,
      "start_date": "2018-10-02",
      "completion_date": "2019-12-27",
      "has_results": true,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 34,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03687827"
    },
    {
      "nct_id": "NCT05205486",
      "title": "Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections"
      ],
      "interventions": [
        {
          "name": "Cefazolin 3gm for Injection USP and Dextrose Injection USP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "B. Braun Medical Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-04-05",
      "completion_date": "2023-07-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 2,
      "location_summary": "Columbus, Georgia • Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05205486"
    },
    {
      "nct_id": "NCT01761773",
      "title": "A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 32,
      "start_date": "2012-12",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • Neptune City, New Jersey",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01761773"
    },
    {
      "nct_id": "NCT00506883",
      "title": "MPC-004 for the Treatment of an Acute Gout Flare",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "High Dose Colchicine (4.8 mg total dose)",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Colchicine (1.8mg total dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2007-04",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506883"
    },
    {
      "nct_id": "NCT00368654",
      "title": "Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Raptiva",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-01",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00368654"
    },
    {
      "nct_id": "NCT05330689",
      "title": "How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "PRP injection dose (<5 billion platelets)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PRP injection dose (between 5 and <10 billion platelets)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PRP injection dose (between 10 and <20 billion platelets)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PRP injection dose (20 billion or greater platelets)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline injection control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-03-06",
      "completion_date": "2022-09-07",
      "has_results": false,
      "last_update_posted_date": "2024-03-26",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05330689"
    },
    {
      "nct_id": "NCT01431274",
      "title": "Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "tiotropium + olodaterol",
          "type": "DRUG"
        },
        {
          "name": "tiotropium",
          "type": "DRUG"
        },
        {
          "name": "olodaterol",
          "type": "DRUG"
        },
        {
          "name": "Respimat",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 2624,
      "start_date": "2011-09",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-07-16",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 35,
      "location_summary": "Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431274"
    },
    {
      "nct_id": "NCT07219797",
      "title": "Study of Monochromatic X-ray Mammography System",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Imaging",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "2-D Monochromatic X-ray Mammography System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Imagine Scientific, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 52,
      "start_date": "2026-06",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-25",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219797"
    },
    {
      "nct_id": "NCT05831124",
      "title": "A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumococcal Disease"
      ],
      "interventions": [
        {
          "name": "Low dose multivalent pneumococcal conjugate vaccine formulation A",
          "type": "OTHER"
        },
        {
          "name": "Low dose multivalent pneumococcal conjugate vaccine formulation B",
          "type": "OTHER"
        },
        {
          "name": "Low dose of multivalent pneumococcal conjugate vaccine control",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard dose multivalent pneumococcal conjugate vaccine control",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "50 Years to 64 Years"
      },
      "enrollment_count": 90,
      "start_date": "2023-04-19",
      "completion_date": "2024-06-26",
      "has_results": false,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-10-28T17:04:46.742Z",
      "location_count": 9,
      "location_summary": "Hialeah, Florida • Hollywood, Florida • Columbia, Maryland + 4 more",
      "locations": [
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Columbia",
          "state": "Maryland"
        },
        {
          "city": "Elkridge",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05831124"
    }
  ]
}